AMG 404 in Patients With Advanced Solid Tumors

  • STATUS
    Not Recruiting
  • End date
    Jul 25, 2025
  • participants needed
    275
  • sponsor
    Amgen
Send
Updated on 5 March 2022
See if I qualify

Summary

To evaluate the safety and tolerability of AMG 404, a monoclonal antibody that binds to PD-1 and inhibits its engagement with ligands, in patients with advanced solid tumors.

Details
Condition Advanced Solid Tumors
Treatment AMG 404
Clinical Study IdentifierNCT03853109
SponsorAmgen
Last Modified on5 March 2022

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note